Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035440 | 0.95 | MAOB (0.68) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL29369517 | 0.90 | MAOB (0.78) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL384341 | 0.90 | MAOB (0.78) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL3214018 | 0.88 | MAOB (0.63) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL6450099 | 0.87 | MAOB (0.65) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL10797158 | 0.86 | MAOB (0.72) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL29466867 | 0.86 | MAOB (0.68) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL1961888 | 0.86 | MAOB (0.53) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL5445458 | 0.85 | KDM4E (0.49) | MAOBMAPTCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31088170 | 0.85 | KDM4E (0.49) | MAOBMAPTCYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563599-B2 | Methods for synthesizing glycinols, glyceollins I and II, compositions of selected intermediates, and therapeutic uses thereof | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | THE UNIVERSITY OF TOLEDO | 2012-05-10 | — | — | US | disclosed |
| US-20110144195-A1 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | XAVIER UNIVERSITY OF LOUISIANA | 2011-06-16 | — | — | US | disclosed |
| WO-2009111428-A2 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144195-A1 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF | GPER1, ESR2, GNE | MAOB 3183/4885SMN1; SMN2 3213/4885MAPT 4369/4885 |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | UGGT1, GCG, UGT8 | MAOB 669/4885SMN1; SMN2 4139/4885MAPT 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.